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ABSTRACT The effects of the selective β2-adrenoreceptor agonist (fenoterol) on the functioning of mouse atrial 
were studied using both tensometry and fluorescent methods. It has been demonstrated that with the use of a 
high concentration of fenoterol (in the range of 1–50 µM), there is a more significant positive inotropic effect 
observed within a shorter period of time. In the case of relatively low doses of fenoterol (1 and 5 µM), its contrac-
tility effects are observed 20 min after the application of agonist, whereby in the case of high concentrations (25, 
50 and 300 µM), the effects appear within the first minutes. During the first 10–15 min, 5 µM fenoterol causes an 
increase in the amplitude of Ca-signals in cardiomyocytes (this indicates an increase in the concentration of Ca 
ions during systole) and the activation of NO synthesis. However, after 20 min, the production of NO decreases; 
while the amplitude of Ca-signals remains high. The application of 50 µM fenoterol leads to a rapid increase in 
the amplitude of Ca-signals: at the same time, it causes a decrease in the production of NO, which we found to 
begin to increase after 10 min of agonist application. It is suggested that the dynamics of the positive inotropic 
effect occurring under pharmacological stimulation of β2-adrenoreceptors depend on the rate of increase in the 
amplitude of Ca-signals and on the degree of NO synthesis.
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INTRODUCTION
One of the mechanisms that regulate the action of the 
heart is based on the interaction of catecholamines 
(adrenaline and noradrenaline) with G protein-cou-
pled β-adrenoreceptors in cardiomyocytes [1, 2]. De-
pending on their sensitivity to pharmacological agents 
and on their structural features, β-adrenoreceptors 
are divided into three types: β1, β2, and β3. All types of 
β-adrenoreceptors are expressed within the heart. The 
function of the β1-adrenoreceptors in the heart is well 
known. Meanwhile, β2-adrenoreceptors have been sub-
jected to much less thorough study: only their func-
tions in the regulation of the vascular tone in the heart 
and the skeletal muscles of bronchial lumen and the 
metabolism of a body have [3].
The concentration of β2-adrenoreceptors is particu-
larly high in atrial cardiomyocytes. While, within the 
entire heart, the content of β2-adrenoreceptors reaches 
30–40% of the total amount of β-adrenoreceptors [2], in 
human atrial cardiomyocytes their content is over 55% 
[4]. The stimulation of β2-adrenoreceptors leads to an 
increase in the contractility of the ventricular cardio-
myocytes in a rat heart, with no significant impact on 
the rate of relaxation [5]. It is believed that the activa-
tion of β2-adrenoreceptors causes a positive inotropic 
reaction without increasing the risk of arrhythmias and 
sudden death of the animal [6]. It should be noted that, 
upon stimulation of β2-adrenoreceptors, the inotropic 
effect might be negative, e.g. in papillary muscles of the 
guinea pig heart [7].
The effect of the stimulation of β2-adrenoreceptors 
on the contractility of ventricular cardiomyocytes is 
defined by the interaction of the receptor with the 
Gs protein, which initiates the adenylyl cyclase cas-
cade causing the activation of protein kinase A. Under 
the action of this kinase,   part of the L-type calcium 
channels could be opened and the conduction of these 
channels enhanced, and consequently the amount of 
Ca ions entering the cytoplasm during action poten-
tial could also increase [8, 9]. However, the activated 
β2-adrenoreceptors stimulate also Gi proteins, which 
inhibit the adenylyl cyclase cascade, thereby limit-
ing the positive inotropic effect produced by the β2-
adrenoreceptor agonists [10, 11]. The activation of Gi 
proteins initiates the phosphoinositol-3-kinase (PI3K)/
protein kinase B cascade, which is aimed at maintain-
ing cell survival, protecting them from the action of 
reactive oxygen speciesand hypoxia [12, 13]. In addi-
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tion, the phosphoinositol-3-kinase (PI3K)/protein ki-
nase B cascade may initiate an increase in the pro-
duction of nitric oxide (NO), which, by affecting the 
guanylate cyclase system, is capable of inhibiting the 
effect of β2-adrenoceptor agonists [14, 15] and  pre-
venting the desensitization of β2-adrenoceptors [16] 
as well. It has been suggested that β2-adrenoreceptors 
play a cardioprotective role, while β2-adrenoreceptor 
agonists can be viewed as promising pharmacological 
agents [13]. Thus, in mice with overexpression of β2-
adrenoreceptors, no heart failure develops and no signs 
of cardiomyocyte damage are revealed against a back-
ground of increased frequency and strength of heart 
contractions, which are observed even in the absence 
of β2-adrenoreceptor activation by endogenous ligands 
[17]. The point is that β2-adrenoreceptors can be spon-
taneously switched into their active state regardless of 
whether there are agonists in the extracellular medium 
or not [18]. It is interesting that, under spontaneous ac-
tivation of β2-adrenoreceptors, contractility increases, 
but the entering calcium current through L-type cal-
cium channels does not change [19].
β2-Adrenoreceptors are very “flexible” molecules 
with several active states (conformations). The confor-
mations define the properties of the receptors, includ-
ing their ability to bind to effector signaling proteins, 
whose role can be played not only by G proteins, but 
also by tyrosine kinase Src, by the factor that con-
trols the Na-H exchange, by arrestin, by the N-eth-
ylmaleimide factor, and by several scaffold proteins 
[20–24]. It was demonstrated recently that different 
agonists can transform β2-adrenoreceptors into forms 
with specific active conformations; hence the reason 
why the type of agonist defines the cell-mediated re-
sponse (this phenomenon is called the “functional se-
lectivity” of agonists) [25]. Fenoterol is one of the most 
widely used drugs in clinical medicine and one of the 
effective short-acting β2-adrenoreceptor agonists. Its 
effects include a significant increase in the cAMP level 
and the activation of mitogen-activated protein (MAP) 
kinase [25] in human airway smooth muscle cells and, 
in endotheliocytes, intensification of the synthesis of 
nitric oxide (NO) [26]. It should be noted that, under the 
action of fenoterol, β2-adrenoreceptors undergoes in-
tensive phosphorylation by G protein-coupled receptor 
kinases, followed by their internalization during clath-
rin-mediated endocytosis. As a result, long-term use 
of fenoterol leads to desensitization and a decrease in 
the amount of the β2-adrenoreceptors on the surface of 
bronchial epithelium [25, 27].  New data on the unique 
properties of fenoterol and its stereoisomers has ap-
peared; this data can be used to design drugs that have 
a high selectivity value and pronounced cardioprotec-
tive properties [28, 29].
The role of β2-adrenoreceptors in atrial cardiomyo-
cytes is not thoroughly understood. There is data in-
dicating that there is an increase in contractility and 
the rate of intake of the calcium current upon stimu-
lation of the atrial β2-adrenoreceptors in guinea pigs, 
cats, and humans [15, 30, 31]. However, in mice with 
overexpression of human β2-adrenoreceptors, the ac-
tivation of atrial β2-adrenoreceptors by isoprenaline 
has a negative inotropic effect, while, under normal 
circumstances, isoprenaline, which affects mostly β1-
adrenoreceptors, has a positive inotropic effect [32, 33]. 
In this work, we studied how various doses of racemic 
fenoterol, a β2-adrenoreceptor agonist widely used in 
medicine, influence the atrial contractility, amplitude 
of Ca-signals, and NO production.
EXPERIMENTAL
Isolated atria of white mice were used in the experiments. 
The standard Krebs solution for warm-blooded animals 
with the following composition was used: 144.0 mM NaCl, 
5.0 mM KCl, 0.1 mM MgCl2, 2.0 mM CaCl2, 1.0 mM NaH-
2PO4, 2.4 mM NaHCO3, 11.0 mM glucose; the solution was 
saturated with oxygen. The pH value of the solutions was 
maintained at 7.2–7.4 at a temperature of 20°C. During 
the experiment, the specimen was stimulated by electri-
cal pulses of suprathreshold amplitude at a frequency of 
0.1–1 Hz via platinum electrodes. In the majority of ex-
periments, the application (20 min) of (±)-fenoterol (Sig-
ma, USA), a β2-adrenoreceptor agonist, at concentrations 
of 1–300 µM was used. In some cases, 0.1 µM ICI-118.551 
(Tocris, USA), a selective blocker of β2-adrenoreceptors 
was applied.
Tensometry
The atrial contraction was registered using a Power-
Lab installation. One end of the isolated atrium was 
tied to a fixed nail, and the other end was linked to a 
nail connected to a strain gauge with a sensitivity of 
0–25 g (AD Instruments). The signals were treated us-
ing Chart software; the contractility was determined 
in grams.
Fluorescent Microscopy
The fluorescent experiments were carried out using 
an OLYMPUS CX41 (with exchangeable monochro-
matic excitation light sources) and an OLYMPUS BX51 
(equipped with the DSU confocal system) microscope 
with a LMPlanFI 20×/0.40 and UPlanSApo 60×/1.20W 
objectives. The images were made using high-speed 
CCD cameras produced by OLYMPUS: a F-View II 
black and white and DP71 color CCD camera. The im-
ages were treated using Cell^A, Cell^P, and ImagePro 
software. The fluorescence intensity was estimated in 
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ness value in pixels.
Measurements of the Intracellular Concentration of 
Calcium Ions. The changes in the concentration of Ca2+ 
were determined using a Fluo-4 dye, which allows 
the Ca2+ concentration to be precisely measured in a 
range from 1 µM to 1 mM. Fluo-4 is weakly fluores-
cent in the absence of Ca2+, but its binding to Ca ions 
leads to an increase in the fluorescence value by a fac-
tor over 100 [34]. Fluo-4-AM (Molecular Probes, USA), 
a membrane-penetrating form of the dye, was used; 
it was dissolved in DMSO (dimethyl sulfoxide, Sigma, 
USA) and stored in the frozen form (for not more than 
a week) in the dark. Just prior to the experiment, a Plu-
ronic F-127 (Molecular Probes, USA) nonionic deter-
gent was added into a Fluo-4-AM batch; the detergent 
facilitates the dissolving of nonpolar Fluo-4-AM in an 
aqueous (physiological) solution. In a work solution, 
the final concentration of Fluo-4-AM was 1 µM, and 
the content of DMSO and Pluronic F-127 was not more 
than 0.0005%. The isolated atrial specimen was held in 
the solution containing 1 µM Fluo-4-AM for 20 min at 
room temperature. Afterwards, the specimen was per-
fused with a physiological solution for 40 min (during 
this period of time, deesterification of Fluo-4-AM in 
the cytoplasm ended and the formation of hydrophilic 
Fluo-4, which cannot pass through the membrane into 
the intracellular medium [34], occurred). Thereafter, 
measurements of the fluorescence in the cardiomyo-
cytes of the isolated atria were made. The fluorescence 
of the dye was excited by short (about 1 s) flashes of 
light with a wavelength of 480 nm and registered us-
ing an emission-color filter that transmits light with 
a wavelength of above 515 nm. During the contrac-
tion-relaxation cycle of the atrial specimen, periodic 
changes in the fluorescence of the Ca sensor, which 
appeared in the form of flashes (“Ca-signals”), were 
observed: the intensity of the fluorescence increased 
during contraction and decreased during relaxation. 
Ca-signals indicate an increase in the concentration of 
Ca ions, which initiate contraction of cardiomyocytes. 
The minimum fluorescence value observed during di-
astole was subtracted from the maximum fluorescence 
value observed during systole, in order to estimate the 
amplitude of the Ca-signals.
Measurements of the Concentration of Nitric Oxide 
(NO).The production of nitric oxide was detected us-
ing a DAF-FM-diacetate marker (Molecular Probes, 
USA), which was excited by light with a wavelength 
of λ = 495 nm; for the registration of fluorescence, an 
emission filter that transmits light with a wavelength 
above 515 nm was used. DAF-FM-diacetate easily per-
meates through the cellular membranes. Inside the cell, 
DAF-FM-diacetate is deacetylated by intracellular es-
terase to DAF-FM. Prior to reacting with NO, DAF-FM 
almost does not fluoresce; but its interaction with NO 
leads to an increase in the fluorescence intensity by a 
factor of more than 160 [29]. DAF-FM was dissolved in 
DMSO and stored in frozen form in a dark place. The 
specimen of the isolated atrium was held in a solution 
containing 2 µM DAF-FM-diacetate for 30 min at room 
temperature. After that, the atrial specimen was per-
fused with a physiological dye-free solution for 20 min 
(the period of time needed for deacetylation of the 
marker to finish [35]). Thereafter, the measurements 
of fluorescence in cardiomyocytes of the isolated atria 
were made.
A statistical analysis was performed using the Ori-
gin Pro software. The results of the measurements 
were presented as mean values ± standard error (n is 
the number of independent trials). The significance of 
the differences was determined in accordance with the 
Student’s test and ANOVA.
RESULTS
Dose-Dependence of the Inotropic Effect of Fenoterol
Amplitude of Contractions. The addition of fenoterol at 
concentrations ranging from 1 to 300 µM led to a sig-
nificant increase in contractility (Fig. 1a, b). The appli-
cation of 1 and 5 µM of fenoterol increased contractility 
to 134 ± 4.4% (p < 0.01, n = 5) and 144.6 ± 5.1% (p < 0.01, 
n = 5), relative to the control value, respectively. Un-
der the action of fenoterol (25 and 50 µM), contractility 
increased even more; i.e. up to 159.7 ± 5.5% (p < 0.01, 
n = 6) and 176.2 ± 6.6% (p < 0.01, n = 8), respective-
ly. However, 300 µM of fenoterol caused an increase 
in contractility only to 143.3 ± 6.5% (p < 0.01, n = 5) 
(Fig. 1c). Since β2-adrenoreceptors are desensitized rel-
atively fast by high doses of agonists, the slight influ-
ence of 300 µM of fenoterol on contractility most likely 
relates to desensitization processes [27, 36].
Time-Course of the Effect. The rate of development 
of the positive inotropic effect of fenoterol varied de-
pending on its concentration: the higher the concen-
tration, the earlier the increase in contractility was ob-
served (Fig. 1a, b). The amplitude began to grow only 
20 min after fenoterol at concentrations of 1 and 5 µM 
was applied, and maximum contractility was observed 
after 30–40 min. When fenoterol was used at concen-
trations of 25 and 50 µM, the contractility increased 
significantly faster: i.e., 15 and 13 min after the addi-
tion of the agonist, contractility reached a maximum. 
300 µM of fenoterol led to maximum contractility just 
after 3 min.
Delayed Effect of Fenoterol. As was mentioned above, 106 | ACTA NATURAE |  VOL. 3  № 2 (9)  2011
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at low concentrations of fenoterol, the positive inotropic 
effect occurs very late, only after 20–25 min (Fig. 1c). 
In order to clarify why the development of the effect 
is so slow, additional experiments in which a solution of 
fenoterol (5 µM) was replaced by a normal Krebs solu-
tion after 20 min (i.e. prior to the beginning of the in-
crease in contractility). The contractility was found to 
increase despite the absence of fenoterol in the solution. 
Ten minutes after the removal of fenoterol from the so-
lution surrounding the atrial specimen, the amplitude 
reached its maximum: 141.6 ± 4.1% relative to the con-
trol value (p < 0.01, n = 8). It then decreased gradually. 
This indicates that the delayed effect observed at low 
concentrations of β2-adrenoreceptors is related to the 
activation of intracellular signal systems, whose action 
develops at a very low rate.
In further experiments, only two concentrations of 
fenoterol were used: 5 µM, at which the delayed effect 
was observed; and 50 µM, at which contractility was 
found to increase rapidly (Fig. 1c). It should be noted 
that, in the presence of the selective β2-adrenoreceptor 
blocker (0.1 µM ICI-118.551), no positive inotropic ef-
fect of fenoterol at concentrations of 5 and 50 µM ap-
pears (data are not presented).
The Effect of Fenoterol on Ca-Signals
The dynamics of the intracellular concentration of 
calcium ions, which initiate the contractions of cadri-
omyocytes, significantly change under the action of 
fenoterol (Fig. 2). Use of a low concentration of fenoter-
ol (5 µM) leads to a gradual increase in the amplitude 
of Ca-signals. After 3 min of application of the  β2-
adrenoreceptor agonist, the amplitude of Ca-signals 
reached 122.6 ± 4.7% (p < 0.05, n = 7); and after 10 min, 
the value of the amplitude was 152.1 ± 4.9% (p < 0.01, 
n = 7) relative to the initial values. After 15 min of ap-
plication of the agonist, the amplitude of Ca-signals 
somewhat declined, but after 20 min, it stabilized at a 
level of 130–140%. Five minutes after the surrounding 
solution was replaced with a fenoterol-free solution, 
the amplitude of Ca-signals was 133.6 ± 4.7% (p < 0.01, 
n = 7). The amplitude of Ca-signals returned to the ba-
а
b
c
F
m
a
x
,
 
%
T
5
0
,
 
m
i
n
Fenoterol, µM
Fenoterol, µM
Fenoterol
50 µM
300 µM
5 µM
C
o
n
t
r
a
c
t
i
l
i
t
y
,
 
%
Time, min
1  10  100
1  10  100 0  10  20  30  40
90
60
30
20
10
0
180
160
140
120
100
80
Fig. 1. Effect of fenoterol on the contractility of the isolated atria. The influence of the various doses of fenoterol on con-
tractility (a) and time-course of the effect (b).Y-axis: а is the maximum amplitude of contractions (Fmax, “0” corresponds 
to the value observed prior to application of fenoterol ); b is the period of time from the moment fenoterol was applied 
to the moment when the amplitude reached 50% of the maximum amplitude of contractions (T50). X-axis: the logarithmic 
scale of concentrations (µM).  (c) The change in the atrial contractility under the action of 5, 50, and 300 µM of fenoterol 
(open and filled circles and filled squares, respectively). Y-axis: the force of contraction, (%) (100% corresponds to the 
level of contractility prior to the application of fenoterol). The beginning of the application of fenoterol is indicated by an 
arrow. The presented data on the change in the atrial contractility under the action of fenoterol applied at concentra-
tions of 1 (n = 5), 5 (n = 5), 25 (n = 6), 50 (n = 8), 300 (n = 5) µM were obtained in independent experiments.RESEARCH ARTICLES
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sal level 60–70 min after fenoterol was removed from 
the intracellular solution. The application of fenoterol 
at high concentrations (50 µM) caused an increase in 
the amplitude of Ca-signals to 121.9 ± 4.9% (p < 0.05, 
n = 7) just after 30 s, and by the third minute, its value 
reached a maximum, 154 ± 4.8% (p < 0.01, n = 7). After 
8 min of application, the amplitude began to decline, 
and 20 min after the application of fenoterol, its value 
was 111.2 ± 4.3% (p < 0.05, n = 7). The amplitude of Ca-
signals was brought to its initial value 50–60 min after 
perfusion of the atrial specimen with a fenoterol solu-
tion was begun.
The Effect of Fenoterol on the Production of Nitric 
Oxide
Under the action of fenoterol, the fluorescence of the 
DAF-FM marker (an indicator of NO production) in 
atrial cardiomyocytes reliably grew (Fig. 3). At low 
doses, fenoterol initiated a gradual increase in the NO 
production; and after 20 min of application of fenoter-
ol, the intensity of the fluorescence grew to 104 ± 0.7% 
(p < 0.05, n = 6). After the removal of fenoterol from 
the surrounding solution, the intensity of the fluores-
cence dropped to 95.0 ± 1.4% (p < 0.05, n = 6) relative 
to the initial level, after which it returned to the base-
line within 5 min. Under the action of a high dose of 
fenoterol, during the first 5 min of application, a de-
crease in the intensity of DAF-FM fluorescence was ob-
served (by the fifth minute of application, the intensity 
was 95.9 ± 0.8% (p < 0.05, n = 6)). After 8 min of appli-
cation of fenoterol, the intensity of the fluorescence be-
gan to grow and reached 103.9 ± 0.6% (p < 0.05, n = 6) 
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Fig. 2. Effect of fenoterol on the 
Ca-signals in cardiomyocytes of the 
isolated atria.
(A)The changes in fluorescence 
of the Fluo-4 Ca-indicator loaded 
into cardiomyocytes of the isolated 
atrium. The pseudo-colored im-
ages illustrate Ca-signals occurring 
in cardiomyocytes of the isolated 
atria per single atrial contraction 
before (a, a’) and after the applica-
tion of fenoterol at concentrations 
of 5 (b, c) and 50 µM (b’, c’). 
Above the images, the time from 
the stimulus is shown (ms): 0, 18, 
88, 158, 228. The scale is 10 µm. 
On the right, the curves represent-
ing changes in the fluorescence 
of Fluo-4 occurring as a response 
to the stimulus are shown. Along 
the Y-axis: the intensity of fluo-
rescence, rel. units (“0” is fluores-
cence before stimulus); along the 
X-axis: time in ms from the stimulus. 
(B) The effect of 5 (n = 7) and 50 
(n = 7) µM fenoterol on the ampli-
tude of Ca-signals (open and filled 
squares, respectively). Changes in 
the amplitude of Ca-signals in the 
absence of fenoterol are shown 
with open circles connected by a 
dash line (Control, n = 5). Along 
the Y-axis: fluorescence (%); along 
the X-axis: time (min). The applica-
tion of fenoterol is indicated with 
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within 20 min. After the atrial specimen was perfused 
with a fenoterol-free solution, the intensity of the fluo-
rescence exceeded the control level for 10–15 min: its 
value was 104.3–106.7% (p < 0.05, n = 6) relative to the 
baseline.
DISCUSSION
The slow development and stability of the effects 
produced by 1 and 5 µM of fenoterol indicate the ac-
tivation of the intracellular signal systems with a 
long-term effect, which is caused by the stimulation 
of β2-adrenoreceptors. In our opinion, the influence of 
fenoterol on the inotropic atrial function can be ex-
plained by the interaction of β2-adrenoreceptors with 
several intracellular signaling cascades that regulate 
the contractility.
The key factor defining the contractility of the car-
diac muscle is the concentration of calcium ions in car-
diomyocytes during systole. The contractions of cardio-
myocytes are initiated by calcium ions, which enter the 
cytosol in two ways. Depolarization of the membrane 
caused by the action potential leads to an opening of 
voltage-dependent calcium channels, through which 
calcium ions influx into the cytoplasm, where they bind 
to the ryanodine receptors (Ca-release channels) of the 
sarcoplasmic reticulum. As a result, calcium ions are re-
leased from the sarcoplasmic reticulum, and their con-
centration in the cytoplasm reaches a maximum. In our 
experiments, the application of fenoterol led to a sig-
nificant increase in the intensity of Ca-signals (Fig. 2); 
this most likely occurs due to an increase in the amount 
of Ca2+ ions entering through the channels of the plas-
ma membrane. It is known that β2-adrenoreceptors, as 
well as β1-adrenoreceptors, bind to Gs proteins, which 
activate the adenylate cyclase that catalyzes the syn-
thesis of cAMP, a secondary messenger. This process 
activates cAMP-dependent protein kinases, which 
phosphorylate the specific target proteins [37]. One of 
the main substrates for protein kinase A is the L-type 
calcium channel, which, in the phosphorylated state, 
has a higher conductance and a higher probability of 
opening up and is activated when the membrane po-
tential values are more negative [9, 31].
The following interesting fact was denoted. At a con-
centration of 5 µM, fenoterol causes slow growth in the 
intensity of Ca-signals, whose amplitude remains high 
after the removal of fenoterol from the solution sur-
rounding the specimen. Simultaneously, the application 
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of 50 µM of fenoterol leads to an increase in the ampli-
tude of Ca-signals (Fig. 2).
There are three possible explanations for this. 
First, it can be suggested that fenoterol begins to af-
fect not only β2-adrenoreceptors at a higher dose, but 
also β1-adrenoreceptors, which activate an additional 
number of calcium channels under the action of pro-
tein kinase A. Thus, the constant characterizing the 
binding of fenoterol (stereoisomers R,R-1 and -2) to 
the β1-adrenoreceptors of HEK cells is estimated to be 
approximately 15–20 µM [28]. In addition, the most ef-
fective concentration of fenoterol, i.e. the concentra-
tion that leads to a maximum increase in the contractil-
ity of human papillary muscle isolated specimens, was 
100 µM; in this case, the effect of fenoterol depended 
on β2- and β1-adrenoreceptors [38]. However, this ex-
planation contradicts our results, according to which 
the selective β2-adrenoreceptor blocker (0.1 µM ICI-
118.551) completely eliminates the positive inotropic 
effect produced by 50 µM fenoterol. The second pos-
sible explanation is the involvement of a large num-
ber of metabotropic β2-adrenoreceptors that cause an 
increase in the production of cAMP and the activation 
of a large number of protein kinase A molecules, which 
in  turn intensify the phosphorylation of Ca-channels, 
rendering them more active [1]. However, the  R,R-
stereoisomer of fenoterol at a concentration of around 
0.5 µM activates almost all β2-adrenoreceptors in rat 
ventricular cardiomyocytes[39]. According to the ap-
proximate estimations made, even at a concentration 
of 2 µM, the racemic fenoterol used occupies around 
90% of the β2-adrenoreceptors of bronchial epithelial 
cells [27]. Consequently, it is most likely that, under the 
action of 5 and 50 µM of fenoterol, an equal number 
of β2-adrenoreceptors is activated. The third sugges-
tion is based on the facts noted to date that, for trans-
duction the signal inside a cell, β2-adrenoreceptors can 
use different signal cascades and/or bind differently 
in terms of efficiency to effector molecules, depending 
on the dose of the agonist [22]. Thus, upon application 
of high doses of the agonist (100 µM isoproterenol), the 
isolated β2-adrenoreceptors can exist in two different 
conformations [40]; in each conformation, the efficiency 
of the interaction of the activated receptor with G pro-
teins and other proteins is different. It is interesting 
to note that as a response to the application of selec-
tively high doses of the agonist, the β2-adrenoreceptor 
begins to activate not only Gs proteins, but also tyros-
ine kinase Src, which is involved in the regulation of 
signal proteins (e.g., MAP-kinase) and phosphorylates 
the β2-adrenoreceptor. The phosphorylated residues 
of β2-adrenoreceptor tyrosine can play the role of a 
dockingsite for other signal molecules [22]. In addition, 
Src-kinase is capable of regulating (including the acti-
vation) L-type Ca-channel function by binding to the 
N-terminal region of the channel α1-subunit and phos-
phorylating it [41]. Most likely, the rapid increase in the 
amplitude of Ca-signals observed under the action of 
50 µM of fenoterol occurs due to the activation of an 
additional pathway (e.g., involving Src-kinase), which 
facilitates the function of the L-type Ca-channels. In 
our opinion, the last suggestion is the most probable 
and should be studied experimentally in the first place.
In the study we performed, the increase in the pro-
duction of nitric oxide in atrial cardiomyocytes occur-
ring under the action of fenoterol was revealed for the 
first time (Fig. 3). The production of nitric oxide is an 
important factor that controls the contractility of car-
diomyocytes. An intensification of the NO production 
may lead to a negative inotropic effect and/or inter-
fere with increasing contractility of cardiomyocytes 
[42]. Such an  effect  by nitric oxide might be associ-
ated with the activation of cGMP-dependent protein 
kinases G, which phosphorylate troponin I, thereby 
decreasing the sensitivity of troponin C to calcium, 
and influence the Ca-channels, thereby decreasing the 
calcium conductance [43, 44]. Since the effect of nitric 
oxide is connected to the activation of the guanylate 
cyclase that is in the “on” state, it produces thousands 
of cGMP molecules; thus, even a slight increase in the 
synthesis of NO can have a significant influence on the 
cell functions [45].
Several hypotheses regarding the mechanisms of 
how β2-adrenoreceptors are linked with the NO syn-
thase responsible for the production of nitric oxide can 
be suggested. β2-Adrenoreceptors have the ability to 
interact with the Gi protein. However, the activated re-
ceptor binds to the Gi protein less readily than it binds 
to the Gs protein [46]. It is assumed that for a longer 
period of time, the activated β2-adrenoreceptors are 
in a state that is characterized by high affinity to the 
Gs protein, while it is in a state in which it is selectively 
bound to the Gi protein for a shorter period [47]. Ac-
cording to the other hypothesis, β2-adrenoreceptors 
can interact with the Gi protein only after having 
been phosphorylated by protein kinase A or kinase of 
G protein coupled receptors [48]. The α-subunits of the 
Gi protein inhibit production of cAMP by adenylate cy-
clases, and the dimers of βγ-subunits affect some ionic 
channels and signal molecules; in particular, they ac-
tivate the PI3K/protein kinase B pathway [1, 49]. One 
of the effectors in this pathway is NO synthase (neural 
and endothelial isoforms), whose activity intensifies af-
ter its phosphorylation by protein kinase B [50]. In rat 
endothelial cells, the application of fenoterol causes an 
increase in the PI3K/protein kinase B-dependent ac-
tivity of the endothelial NO synthase [26]. However, in 
rat ventricular and cat atrial cardiomyocytes, fenoterol 110 | ACTA NATURAE |  VOL. 3  № 2 (9)  2011
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(0.1 µM) did not activate the pathway associated with 
the Gi protein and NO production, and its effect on con-
tractility was exclusively associated with the Gs pro-
tein [15, 51].
The activation of the Gi-protein in HEK293 cells 
under the action of fenoterol has been recently found 
to be independent of ERK1/2 kinase (extracellular 
signal-regulating kinases) [29]. In rat cardiomyocytes, 
ERK1/2 is phosphorylated and activated in the NO-de-
pendent pathway [52]. Most likely, β2-adrenoreceptors 
are capable of activating NO synthase independently 
of the G-protein. The β-arrestin 2 protein, which in-
teracts simultaneously with β2-adrenoreceptors and 
NO synthase, may play the role of a factor that con-
jugates the activation of the receptor and the increase 
in NO production [43]. Src kinase stimulated by β2-
adrenoreceptors phosphorylates the Tyr83 residue of 
the endothelial NO synthase, thereby increasing the 
synthesis of NO [54]. In addition, the activation of NO 
production is facilitated by the complex of calcium ions 
with calmodulin [42]; that is why an increase in the pro-
duction of nitric oxide is most likely partially caused by 
an increase in the concentration of calcium ions due to 
the high activity of L-type calcium channels.
It should be noted that in this work the production 
of nitric oxide started to increase almost immediately 
after the application of a low concentration of fenoterol, 
while at a high concentration, fenoterol caused a de-
crease, firstly, and then an increase in NO synthesis. 
Most likely, in the latter case, a dramatic increase in the 
production of cAMP firstly had a negative influence on 
the functioning of NO synthase (our unpublished data), 
and then the activating action of signals appeared from 
β2-adrenoreceptors and an increased calcium level.
Upon consideration of the effects of the activation 
of β2-adrenoreceptors, it should not be forgotten that 
β2-adrenoreceptors can directly interact with the factor 
that regulates the Na/H exchange, the N-ethylmaleim-
ide-sensitive factor (that controls the internalization 
of the receptors and the interaction with Gi-proteins), 
and the scaffold proteins that connect adrenorecep-
tors with protein kinase A, C, phosphatase 2A, and 
L-type calcium channels [20, 22–24]. As a result, the 
dimers of β2-adrenoreceptors can accumulate around 
the macromolecular signal complex which provides 
a “coordinated” response by a cell to their activation 
[55, 56]. Moreover, β2-adrenoreceptors, calcium chan-
nels, endothelial NO synthase, NADPH oxidase, and 
other regulatory molecules are colocalized in caveolae, 
small invaginations of the plasma membrane enriched 
in cholesterol and caveolin [55]. That is why the effects 
of β2-adrenoreceptor activation in vivo can be associ-
ated with changes in the activity of a large number of 
regulatory molecules in limited regions of the cell.
β2-Adrenoreceptors are known to exhibit a rapid loss 
of  sensitivity to agonists, followed by a dramatic de-
crease in the number of receptors [27, 36]. Taking this 
into account, it can be suggested that fenoterol initi-
ates processes that interfere with the desensitization 
of β2-adrenoreceptors, which explains the stability of 
the effect of fenoterol on the amplitude of contrac-
tions and Ca-signals. Nitric oxide directly affects β2-
adrenoreceptors and the proteins involved in the de-
sensitization of β2-adrenoreceptors (G protein-coupled 
receptor kinases) via S-nitrosylation. As a result, it pre-
vents a decline in the sensitivity of the receptors, which 
occurs under the action of the agonist, and a decrease 
in the amount of receptors [16, 53]. As a response to 
the activation of β2-adrenoreceptors, dynamin, a small 
GTPase that participates in endocytosis, undergoes S-
nitrosylation; this transformation boosts its ability to 
polymerize and form a contractive “collar” [57]. Thus, 
the prolonged effect of fenoterol might be explained 
by the action of nitric oxide on receptors, G protein-
coupled receptors, and dynamin. On the one hand, the 
increase in NO production that occurs under the action 
of fenoterol facilitates the closing of caveolae (i.e. the 
narrowing of the pore that connects an extracellular 
medium with the cavity of caveolae), in which the ago-
nist molecules are captured; and on the other hand, it 
provides long-term activity of β2-adrenoreceptors. In 
this case, even the removal of fenoterol from an extra-
cellular medium does not cause a rapid decline in the 
effects.
CONCLUSIONS
Relying on the data obtained in this work, the following 
can be suggested. The activation of β2-adrenoreceptors 
with low doses of the agonist simultaneously initiates 
signal cascades, which have differently directed effects 
on atrial contractility. That is why the positive inotropic 
effect produced by the agonist does not occur at the 
beginning. However, the production of nitric oxide de-
clines, while the amplitude of Ca-signals remains high; 
this leads to an increase in contractility. In the case of 
activation of β2-adrenoreceptors with high doses of the 
agonist, the pathway associated with a dramatic in-
crease in the amplitude of Ca-signals is activated first, 
while the increase in the production of nitric oxide is 
“delayed”; that is why a significant, positive inotropic 
effect of the agonist is observed. The hypothetic two-
component differently directed mechanism which 
underlies the changes in the atrial contractility occur-
ring upon activation of β-adrenoreceptors by fenoterol 
(racemic) requires a more detailed experimental study. 
The pharmacological approach involving the applica-
tion of nitric oxide synthesis blockers, the adenylate 
cyclase system, L-type calcium channels, ryanodine RESEARCH ARTICLES
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receptors, and probably endocytosis inhibitors would 
allow to shed more light on the pathways of the effects 
produced by the β2-adrenoreceptors of atrial cardiomy-
ocytes, thereby providing an answer to the questions 
raised in this work. 
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